The burden of chronic drug-refractory focal onset epilepsy: Can it be prevented?
Epilepsy & Behavior · 2023-11 · 148 · 109435
DOI: 10.1016/j.yebeh.2023.109435 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Epilepsy & Behavior, 2023-11. Verfasst von Elinor Ben-Menachem und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Gothenburg, Gothenburg, Sweden. Electronic address: elinor.ben-menachem@neuro.gu.se. Hauptthemen laut MEDLINE: Epilepsy, Drug Resistant Epilepsy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Angelini Pharma.
Abstract (Originalsprache)
Despite the many therapeutic options for epilepsy available today, a third of patients still have poorly controlled epilepsy. Over the years, their transition through lines of treatment exposes them to increased risk of disease progression, mortality, morbidity, mental distress, and not least significantly impaired quality of life (QoL). The present review explores the multiple factors contributing to the impairment of health-related QoL in PWE-including both seizure-related and non seizure-related. The analysis aims to identify potential areas of intervention and strategies for a more holistic approach to epilepsy care and inform policy-makers and healthcare providers in their approach to this condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Gothenburg, Gothenburg, Sweden. Electronic address: elinor.ben-menachem@neuro.gu.se.
- Neurology/Center for Epilepsy, Stroke Unit and Neurological Rehabilitation, Vivantes Humboldt Hospital, Berlin, Germany. Electronic address: Bettina.Schmitz@vivantes.de.
- University of Eastern Finland, Finland. Electronic address: Reetta.Kalviainen@pshyvinvointialue.fi.
- Department of Neurology, Royal Victoria Infirmary, Queen Victoria Rd, Newcastle-Upon-Tyne NE1 4LP, United Kingdom; Translational and Clinical Research Institute, Henry Wellcome Building, Framlington Place, Newcastle-Upo…
- Department of Neurology, George Washington University, Boston, United States. Electronic address: KleinP@Epilepsydc.com.
Förderung
- Angelini Pharma
Zitieren
APA
Ben-Menachem, E., Schmitz, B., Kälviäinen, R., Thomas, R. H., & Klein, P. (2023). The burden of chronic drug-refractory focal onset epilepsy: Can it be prevented?. Epilepsy & Behavior, 148, 109435. https://doi.org/10.1016/j.yebeh.2023.109435
Vancouver
Ben-Menachem E, Schmitz B, Kälviäinen R, Thomas RH, Klein P. The burden of chronic drug-refractory focal onset epilepsy: Can it be prevented?. Epilepsy & Behavior. 2023;148:109435. doi:10.1016/j.yebeh.2023.109435
BibTeX
@article{BenMenachem2023,
author = {Ben-Menachem, Elinor and Schmitz, Bettina and Kälviäinen, Reetta and Thomas, Rhys H and Klein, Pavel},
title = {The burden of chronic drug-refractory focal onset epilepsy: Can it be prevented?},
journal = {Epilepsy & Behavior},
year = {2023},
volume = {148},
pages = {109435},
doi = {10.1016/j.yebeh.2023.109435}
}
EUVIMED